Schizophrenia D012559

Psychiatry and Psychology [F] » Mental Disorders [F03] » Schizophrenia Spectrum and Other Psychotic Disorders » Schizophrenia

Description

A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.   MeSH

Subtype Terms (5)

Schizophrenia, Catatonic
1 approved drug

Schizophrenia, Disorganized
2 approved drugs

Schizophrenia, Paranoid
10 drugs (7 approved, 3 experimental)

Schizophrenia, Treatment-Resistant
8 drugs (6 approved, 2 experimental)


Phase 4 Indicated Drugs (103)

Phase 3 Indicated Drugs (96)


Organization Involved with Phase 4 Indications (228)

Aalborg University

Aarhus University

Abbott

Abdi Ibrahim Pharmaceuticals

Addis Ababa University

All India Institute of Medical Sciences

Amanuel Mental Hospital, Addis Ababa, Ethiopia

Ambulatório de Bipolaridade

American Legion of Iowa Foundation

American Psychiatric Association

Amylin

Astellas

AstraZeneca

Augusta University

Azur Pharma, Inc

Ballarat Health Services

Beer-Yaacov MHC

Beer Yaakov and Ness Ziona Mental Health Center

Beijing HuiLongGuan Hospital

Ben Gurion University

Brain & Behavior Research Foundation

Brentwood Biomedical Research Institute

Bristol-Myers Squibb

Bronx Psychiatric Center

Capital Medical University

Cardiff University

Case Western Reserve University

Central Institute of Psychiatry, Ranchi, India

Central Mental Clinic for Outpatients of Baku City

Central South University

Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec

Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine

Centro de Investigación Biomédica en Red (CIBER)

Cephalon

Cha Medical University

Chang Gung University

Chonbuk National University

Chongqing Medical University

Chonnam National University

CJ HealthCare Corp.

Collaborative Neuroscience Network

Columbia University

Cornell University

Creighton University

Daewoong Pharmaceutical Co. LTD.

Dartmouth University

Department of Veteran Affairs

Duke University

Emek Medical Center

Emory University

Federal University of Rio Grande do Sul

Forensic Psychiatric Institute

Free University of Berlin

Friedrich Schiller University

Fundació Sant Joan de Déu

German Federal Ministry of Education and Research

German Research Network On Schizophrenia

Government of Korea

Government of Taiwan

Guangzhou Medical University

Guangzhou Psychiatric Hospital

Hamilton Health Sciences Corporation

Handok Pharmaceuticals Co., Ltd.

Harvard University

Henan Medical University

Hospital Permai

Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico

Huazhong University of Science and Technology

Humboldt University

Hunan Mental Hospital

Icahn School of Medicine at Mount Sinai

Indiana University

Indivior Inc.

Inje University

International Schizophrenia Foundation

Janssen Pharmaceutica NV

Jiangxi Mental Hospital

Jiao Tong University

Johannes Gutenburg University

Julius-Maximilians University

Kai-Suan Psychiatric Hospital

Kaohsiung Medical University

Kettering Health Network

Kunming Medical University

Lilly Foundation

Ludwig Maximilians University

Lundbeck

Manhattan Psychiatric Center

Mansoura University

Mario Negri Institute

Martin Luther University

Mclean Hospital

McMaster University

Medical College of Wisconsin

Medical University Innsbruck

Medical University of Lodz

Melbourne Health

Michael J. Gill Mental Health Clinic

Michigan State University

Monash University

Moorgreen Hospital, Southampton

Nanjing Medical University

National Health and Medical Research Council, Australia

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute of Mental Health and Neuro Sciences, India

National Institute of Mental Health (NIMH)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute on Drug Abuse (NIDA)

National Institutes of Health (NIH)

National Natural Science Foundation of China

National Taiwan University

Neurocentria, Inc.

New York University

Niuvanniemi Hospital

University of California, Davis

University of California, Irvine

University of California, Los Angeles

University of California, San Diego

University of California, San Francisco

University of Cantabria

University of Chicago

University of Cologne

University of Connecticut

University of Copenhagen

University of Duesseldorf

University of Duisburg-Essen

University of Erlangen-Nuremberg

University of Georgia

University of Ghana

University of Goettingen

University of Heidelberg

University of Helsinki

University of Illinois at Chicago

University of London

University of Malaya

University of Manchester

University of Mannheim

University of Maryland

University of Massachusetts

University of Medicine and Dentistry of New Jersey

University of Melbourne

University of Miami

University of Michigan

University of Missouri, Kansas City

University of Montreal

University of Nevada

University of Nevada, Reno

University of North Carolina at Chapel Hill

University of Oxford

University of Pittsburgh

University of Regensburg

University of Rochester

University of South Carolina

University of Toronto

University of Tuebingen

University of Ulsan

University of Utah

University of Verona

University of Vienna

University of Washington

Utrecht University

Vanderbilt University

Vanguard Research Group

Veterans Medical Research Foundation

Wallace Kettering Neuroscience Institute

Washington University in St. Louis

Western Norway Regional Health Authority

Yale University

Yeshiva University

Yonsei University

YuLi Hospital

Organization Involved with Phase 3 Indications (100)

Organization Involved with Phase 2 Indications (113)

Organization Involved with Other Experimental Indications (55)

Hierarchy Tree View


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.